Does bolusing intravenous administration sets with monoclonal antibodies reduce chair time in the oncology outpatient setting? a protocol for a randomized controlled trial.
Introduction: Commencing prescribed drugs at the prescribed rate without bolusing the intravenous (IV) administration set with the drug, can increase the time patients spend receiving their treatment. There is an absence of research reporting on bolusing practices in the oncology setting. Clinical O...
| Published in: | Vascular Access Vol. 17; no. 3; pp. 8 - 24 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | protocol tables/charts Journal Article |
| Published: |
Canadian Vascular Access Association
Fall/Winter2023
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=177240851&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 177240851 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 19136692 6N6R jtl: Vascular Access issn: 19136692 maglogo: N pubinfo: dt: Fall/Winter2023 vid: 17 iid: 3 pid: 20417 pub: Canadian Vascular Access Association place: Hamilton, Ontario artinfo: ui: 177240851 177240851 177240851 177240851 ppf: 8 ppct: 16 formats: fmt: @attributes: type: P tig: atl: Does bolusing intravenous administration sets with monoclonal antibodies reduce chair time in the oncology outpatient setting? a protocol for a randomized controlled trial. aug: au: Gavin, Nicole Boyte, Francesca Matthews, Robyn Button, Elise Jones, Lee Hayes, Therese Partridge, Grant Smith, Michael Kennedy, Glen Eastgate, Melissa affil: Royal Brisbane and Women's Hospital, Herston, Queensland, Australia sug: subj: Administration, Intravenous Antibodies, Monoclonal Administration and Dosage Neoplasms Drug Therapy Oncology Outpatient Service Australia Length of Stay Australia Randomized Controlled Trials Infusions, Intravenous Injections, Intravenous Antibodies, Monoclonal Adverse Effects Incidence Drug Hypersensitivity Epidemiology Patient Safety Intravenous Nursing ab: Introduction: Commencing prescribed drugs at the prescribed rate without bolusing the intravenous (IV) administration set with the drug, can increase the time patients spend receiving their treatment. There is an absence of research reporting on bolusing practices in the oncology setting. Clinical Oncology Society of Australia (COSA) guidelines mandate that IV administration sets should not be primed with chemotherapy, this results in patients receiving only saline or other priming solution during the initial stages of each infusion and extends chair time. This study seeks to evaluate the effect, of delivering this priming solution as a bolus, on length of stay. Methods and analysis: A single-centre, randomized controlled trial with a two-group design will compare the chair times for patients receiving IV monoclonal antibodies via two methods: (1) priming of IV administration sets (standard care); and (2) priming the IV administration set followed by a 16 mL drug bolus (intervention). There will be a sample size of 128 participants. The primary outcome will evaluate whether bolusing an IV administration set with a monoclonal antibody will reduce chair time. The secondary outcome is incidence of hypersensitivity reaction. Ethics and dissemination: This randomized controlled trial has ethical approval from the Royal Brisbane and Women's Hospital Human Research and Ethics Committee (HREC/2020/QRBW/68664) and Queensland University of Technology Human Research and Ethics Committee (2021000281). Recruitment commenced 12th of July 2021. Introduction : Commencer à administrer les médicaments prescrits à la vitesse indiquée sans ajouter de bolus au dispositif d'administration intraveineuse peut allonger le temps de traitement des patients. Il n'existe pas de rapport de recherche sur les pratiques de bolus dans le domaine de l'oncologie. Les directives de la Clinical Oncology Society of Australia (COSA) stipulent que les lignes de perfusion ne doivent pas être amorcées par l'administration d'agents chimiothérapeutiques. Autrement dit, en début de perfusion, les patients ne reçoivent que du sérum physiologique ou une autre solution d'amorçage, ce qui prolonge la séance de traitement. Cette étude vise à évaluer l'effet de l'administration de cette solution d'amorçage sous forme de bolus sur la durée de la séance. Méthodes et analyse : Il s'agit d'un essai contrôlé randomisé, réalisé dans un seul centre et portant sur deux groupes, qui compare la durée de traitement des patients recevant des anticorps monoclonaux par voie intraveineuse selon deux méthodes : (1) amorçage des dispositifs d'administration intraveineuse (traitement standard) ; et (2) amorçage du dispositif d'administration intraveineuse suivi d'un bolus de médicament de 16 ml (intervention). La taille de l'échantillon sera de 128 participants. L'évaluation primaire établira si l'administration d'un bolus d'anticorps monoclonal sur un dispositif d'administration intraveineuse réduit le temps de traitement. L'évaluation secondaire est l'incidence d'une réaction d'hypersensibilité. Éthique et diffusion : Cet essai contrôlé randomisé a reçu l'approbation éthique du Comité d'éthique et de recherche humaine de l'Hôpital Royal Brisbane et pour femmes (HREC/2020/QRBW/68664) et du Comité d'éthique et de recherche avec des êtres humains de l'Université de technologie du Queensland (2021000281). Le recrutement a débuté le 12 juillet 2021. pubtype: Academic Journal doctype: protocol tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|